Mode
Text Size
Log in / Sign up

Meta-analysis links influenza vaccination to lower mortality in acute heart failureFlu Shot Linked to Lower Death Risk in Heart Failure Patients

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider influenza vaccination in patients with acute heart failure, recognizing that mortality benefit is observational and not causal.

This meta-analysis pooled data from 5 observational studies examining the association between influenza vaccination and outcomes in patients hospitalized with acute heart failure (AHF) decompensation. The primary outcome was 1-year all-cause mortality, with secondary outcomes including in-hospital mortality, 90-day mortality, and hospitalization after discharge.

For 1-year all-cause mortality, the pooled adjusted hazard ratio was 0.89 (95% CI 0.83-0.96), indicating a reduced risk in vaccinated patients. Similarly, 90-day mortality showed a pooled adjusted HR of 0.86 (95% CI 0.76-0.96). In-hospital mortality had an adjusted odds ratio of 0.85 (95% CI 0.70-1.01), which was not statistically significant. No effect was observed for hospitalization following discharge.

The authors note several limitations: all included studies were observational, so results could be subject to residual confounding, and causality cannot be directly inferred. Absolute risk reductions were not reported, and the certainty of evidence is low.

For clinicians, influenza vaccination appears associated with lower short- and long-term all-cause mortality in patients with decompensated HF, but this association should be interpreted cautiously. Vaccination remains recommended for patients with heart failure based on broader evidence, but this meta-analysis does not establish a causal mortality benefit.

A new analysis of five observational studies suggests that getting a flu shot may help people with acute heart failure live longer. The review looked at patients who were hospitalized for worsening heart failure and compared those who received the influenza vaccine with those who did not.

Over one year, vaccinated patients had about an 11% lower chance of dying from any cause. The benefit was also seen at 90 days, with a 14% lower risk of death. However, the vaccine did not appear to reduce the chance of being readmitted to the hospital after discharge.

It is important to note that these studies were observational, meaning they cannot prove that the flu shot directly caused the lower death rates. Other factors, such as healthier habits in vaccinated people, could have influenced the results. The researchers caution that more rigorous studies are needed to confirm the findings.

Despite these limitations, the flu vaccine is safe and recommended for most people with heart failure. This analysis adds to the evidence that vaccination may offer additional protection beyond preventing the flu itself. Patients should discuss vaccination with their healthcare provider.

What this means for you:
Flu vaccination is associated with lower short- and long-term death risk in acute heart failure, but causality is not proven.

Study Details

Study typeMeta analysis
EvidenceLevel 1
Follow-up12.0 mo
PublishedMay 2026
View Original Abstract ↓
AIMS: In patients with heart failure (HF) influenza vaccination has shown beneficial effects in preventing cardiac decompensations. However, no conclusive results have been achieved in the few studies that have evaluated the impact of vaccination during episodes of acute HF (AHF) decompensation. We conducted a systematic review and meta-analysis to determine the possible effects of influenza vaccination on all-cause mortality in patients diagnosed with AHF. METHODS: PubMed, Medline, Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews databases were searched for longitudinal studies comparing patients with AHF vaccinated against influenza with unvaccinated patients. The primary outcome selected for meta-analysis was 1-year all-cause mortality, and secondary outcomes consisted of other outcomes reported in at least in two different studies. Statistical heterogeneity was determined by calculating the I² statistic. Individual adjusted results were pooled using a random effects model. Sensitivity analysis was run for the primary outcome by removing each individual study and then re-doing the meta-analysis. RESULTS: Up to 30 June 2025, five observational cohort studies examining the effect of influenza vaccination on 1-year all-cause mortality in AHF patients had been published. Statistical heterogeneity was low (I2 = 33.7%), meaning that between-study results were consistent. Pooled analysis of confounder-adjusted hazard ratio (HR) for all-cause mortality in vaccinated patients was 0.89 (95% CI 0.83-0.96) compared with unvaccinated patients. All sensitivity analyses rendered very similar results. In-hospital and 90-day mortality were reported in three and two studies and showed similar reductions in risk, with an adjusted odds ratio of 0.85, 95% CI 0.70-1.01, and adjusted HR of 0.86, 95% CI 0.76-0.96; respectively. Isolated data from single studies suggest no effect on hospitalization following discharge after the AHF episode. CONCLUSIONS: Influenza vaccination is associated with a lower short- and long-term all-cause mortality in patients with decompensated HF; however, as all the studies included in this meta-analysis were observational, these results could be subject to residual confounding and causality cannot be directly inferred from them.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.